News blog
Panel rejects experimental chronic fatigue syndrome drug
A chronic fatigue syndrome drug that spent decades in clinical development and won fervent patient support, has been turned down for approval by a committee of advisers to the US Food and Drug Administration (FDA) who voted 9-4 against it. The drug, named Ampligen (rintatolimod), has not been shown to be effective or safe, the committee determined on 20 December.
Recent comments on this blog
Experiments reveal that crabs and lobsters feel pain
US research ethics agency upholds decision on informed consent
Chemistry credit disputes under the spotlight
Chemistry credit disputes under the spotlight
Contamination created controversial ‘acid-induced’ stem cells